The CBSE Class 12 accountancy sample paper for the 2025–26 session outlines the exam pattern, marks distribution and key focus areas for the 2026 board examination. The paper follows the previous ...

As the Bihar School Examination Board (BSEB) gears up to commence the Class 12 final examinations from February 2, 2026, students are entering the most crucial phase of their preparation. With just a ...

The best new features and fixes in Python 3.14 Released in October 2025, the latest edition of Python makes free-threaded ...

Williams, A. and Louis, L. (2026) Cumulative Link Modeling of Ordinal Outcomes in the National Health Interview Survey Data: Application to Depressive Symptom Severity. Journal of Data Analysis and ...

The Bermuda Triangle may not be the biggest mystery of the Atlantic. In a new study published in the journal Geophysical Research Letters, scientists believe they have discovered the reason why ...

After weeks of what had been tightly buttoned talks between the parties, Senate Democrats have delivered their latest counteroffer on the crypto market structure bill, outlining a set of demands ...

Shareholders were extremely pleased by the biotech's latest news from the lab. This concerned its pipeline weight-loss drug aleniglipron. Structure, which concentrates on metabolic diseases with a ...

The South Florida Water Management District's Python Elimination Program awards cash prizes to python removal agents. Kevin Pavlidis was the top winner for November, earning $2,500 for removing the ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

WASHINGTON, Dec 8 (Reuters) - Scientists have observed the largest-known rotating structure in the cosmos - a gargantuan thread-like assemblage of hundreds of galaxies, gas and dark matter that makes ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...